Abbott Laboratories | ABT.USX
United States - USD

Stock Exchange: NYSE

Symbol: ABT

Sector: Healthcare

Industry: Medical Devices

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories Stats

Previous close:Daily change:
117.13-1.02%
52-Week High:52-Week Low:
121.6499.71
Market Cap:Beta:
201.1 Billion0.72

Abbott Laboratories Key Financials

P/E Ratio:Revenues:Revenue Growth:Gross Margin:
35.237141.2 Billion4.90%55.91%
Dividend Yield:Net Income:Earnings Growth:Net Income Margin:
1.88%5.7 Billion14.60%13.99%
P/E Ratio:Revenues:
35.237141.2 Billion
Dividend Yield:Net Income:
1.88%5.7 Billion
Revenue Growth:Gross Margin:
4.90%55.91%
Earnings Growth:Net Income Margin:
14.60%13.99%
ParametersStocks Investing
Stock CurrencyUSD
Dividend PayingYes
Fractional SharesNo
Maximum Shares100 Shares
Tick value per 1 share0.01 USD
Trading Commission0%
Minimum Price Increment0.01
Limit and Stop Levels0.0
Negative balance protectionNo
Swap free days allowanceN/A
Own the underlying AssetNo
Platform symbolABT.USX
Disclaimer: This material is provided by third-party data sources as a general marketing communication for information purposes only and does not constitute an independent investment research. Nothing in this communication contains, or should be considered as containing, an investment advice or an investment recommendation or a solicitation for the purpose of buying or selling of any financial instrument. All information provided is gathered from reputable sources and any information containing an indication of past performance is not a guarantee or reliable indicator of future performance. Users acknowledge that any investment in CFDs and Physical Stocks products is characterized by a certain degree of uncertainty and that any investment of this nature involves a high level of risk for which the users are solely responsible and liable. We assume no liability for any loss arising from any investment made based on the information presented here.
高风险投资警告: 差价合约 (CFD) 是一种以保证金交易的复杂金融产品。交易差价合约具有高风险。您可能亏损所有本金。这些产品可能并不适合所有人,您应确保了解所涉及的风险。如有必要,请寻求独立的专家建议,并仅使用您可以承受损失的资金进行投资。请仔细考虑此类交易是否适合您,同时考虑所有相关情况以及您的个人财务资源。我们不建议客户将所有账户余额用于满足保证金要求。客户可以通过要求更改杠杆比例来降低风险水平。更多有关信息,请参阅 HYCM 的风险披露。
免責聲明: 此頁面內容僅供參考,並不作為推薦或建議。HYCM 發佈的宣傳中包含的任何過去表現的參考或模擬不能作為未來結果的可靠指標。客戶對其在 HYCM 的所有業務或投資單獨負責。
区域限制:我们不向特定司法管辖区(例如阿富汗、比利时、香港、美国和其他一些地区)的居民提供服务。更多详情请参考我们的
幫助中心

HYCM Limited is authorized and regulated under the Dubai Financial Services Authority with license number F000048.

版權所有© 2020 HYCM